Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
CD40 – CD40L Pathway
CD40 is a member of the TNF receptor family expressed by antigen-presenting cells (APCs) and B cells whereas its ligand, CD40L (CD154), is expressed by activated T cells. Interaction between CD40-CD40L stimulates cytokines secretion of B cells with subsequent T cell activation and antitumor immunity. This T cell priming effect of the CD40-CD40L pathway might be a useful approach in anticancer immunotherapy.
LIT: Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists: G.L. Beatty, et al.; Expert Rev. Anticancer Ther. 17, 175 (2017) • Multiple effects of CD40-CD40L axis in immunity against infection and cancer: A. Ara, et al.; Immunotargets Ther. 7, 55 (2018)
NEW: CD40L (human) ELISA Kit - Biomarker for Autoimmune Diseases & Cancers
The CD40L (human) ELISA Kit (Prod. No. AG-45B-0018) is a sandwich ELISA for specific quantitative determination of human soluble CD40L in serum, plasma and cell culture supernatants. This ELISA Kit shows a very high specificity and sensitivity (20pg/ml).
B Cell Expansion: Highly Potent B Cell Activators and T Cell Priming Reagents
CD40 activation tools can be used to expand B cells, which, as antigen-presenting cells (APCs), are as effective as dendritic cells and promises to streamline the generation of antitumor CD8+ T cells. Several studies show that usage of the agonistic anti-CD40 antibody (FGK45) (Prod. No. AG-20B-0036PF) and MultimericCD40L (Prod. No. AG-40B-0010) are strong stimulators of antitumor immunity.
LIT: R.S. Kornbluth, et al.; Int. Rev. Immunol. 31, 279 (2012) • K.T. Byrne & R.H. Vonderheide; Cell Rep. 15, 2719 (2016)
POTENT CD40L (human) (multimeric) (rec.) (Prod. No. AG-40B-0010)
NEW CD40L (human) (multimeric) (rec.) (Certified Serum Grade) (Prod. No. AG-40B-0010CSG)
NEW CD40L (human) (multimeric) (rec.) (Animal Free) (Prod. No. AG-40B-0010AF)
|
Figure: CD40L (human) (multimeric) (rec.) (Prod. No. AG-40B-0010), CD40L (human) (multimeric) (rec.) (Certified Serum Grade) (Prod. No. AG-40B-0010CSG) or CD40L (human) (multimeric) (rec.) (Animal Free) (Prod. No. AG-40B-0010AF) do not need an enhancer to induce B cell activation. |
 |
POTENT anti-CD40 (mouse), mAb (FGK45) (Prod. No. AG-20B-0036)
|
Figure: Systemic immune activation by CD40 ligation. Mice were sacrificed on day 8 after daily treatment on day 4-7 with FGK45 or control. FGK45 treatment elevated splenocyte numbers. *P < 0.005. Data represent mean ± SD for three to four mice per group. |
 |
Biologically Active CD40 and CD40L Proteins
| Product Name | PID | Source | Endotoxin | Species |
| CD40 (human):Fc (human) (rec.) | AG-40B-0083 | HEK 293 cells | <0.01EU/µg | Human, Mouse |
| CD40 (human):Fc (human) (rec.) | CHI-HF-210CD40 | CHO cells | <0.06EU/µg | Human |
| CD40 (human)-muIg Fusion Protein |
ANC-504-020 |
CHO cells | n.d. | Human |
| CD40L (mouse) (multimeric) (rec.) |
AG-40B-0020 |
CHO cells | <0.01EU/µg | Human, Mouse |
| CD40L (human) (multimeric) (rec.) |
AG-40B-0010 |
CHO cells | <0.01EU/µg | Human |
| CD40L (human):Fc (human) (rec.) | CHI-HF-210CD40L | CHO cells | <0.06EU/µg | Human |
| CD40L (human)-muCD8 Fusion Protein |
ANC-505-020 |
CHO cells | n.d. | Human |
| CD40L (rat) (multimeric) (rec.) | AG-40B-0107 | CHO cells | <0.02EU/µg | Human, Mouse, Rat |
VALIDATED Antibodies for CD40 and CD40L Research
| Product Name | PID | Isotype | Applications | Species |
| CD40 (mouse), mAb (FGK45) (PF) | AG-20B-0036PF | Rat IgG2a | FACS, FUNC | Mouse |
| CD40 (human), mAb (BE-1) |
ANC-189-020 |
Mouse IgG1 | FACS, FUNC, IP | Human |
| CD40 (human), mAb (EA-5) |
ANC-300-020 |
Mouse IgG1 | FACS, FUNC | Human, Rat |
| CD40L (human), mAb (rec.) (blocking) (hu5c8) | AG-27B-6002PF | Human IgG1κ | FUNC, WB | Human, Dog |
| CD40L (human), mAb (24-31) |
ANC-353-020 |
Mouse IgG1 | FACS, FUNC, IHC, WB | Human, Primate |